4.6 Article

CRABP2-A novel biomarker for high-risk endometrial cancer

Journal

GYNECOLOGIC ONCOLOGY
Volume 167, Issue 2, Pages 314-322

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2022.09.020

Keywords

CRABP2; Endometrial cancer; Biomarker; Retinoic acid

Funding

  1. Precision Oncology Ireland
  2. Science Foundation Ireland Strategic Partnership Programme [18/SPP/3522]
  3. AECC, Grupos estables translacionales

Ask authors/readers for more resources

The elevated expression of CRABP2 in endometrial cancer patients is associated with poor clinical outcomes and functional implications. These findings provide important insights into the pathogenesis and prognosis of endometrial cancer.
Objective. Investigate the clinical and functional implications of elevated CRABP2 expression in endometrial cancer (EC) patients. Methods. Patients were stratified into high and lowCRABP2 expression groups using a decision tree classifier. Univariate andmultivariate statistical analyses determined the prognostic and clinicopathological consequences of increased CRABP2 expression. A CRABP2 gene signature was generated using differential expression analysis, and analyzed using network-based approaches. The findings were validated in The Clinical Proteomic Tumor Analysis Consortium(CPTAC), a newly generated cohort of 120 endometrial tissues, and The Cancer Dependency Map (DepMap). Results. 60 (11%) patients in TCGA had high CRABP2 expression, whilst 468 (89%) had low expression. High expression was associated with serous EC, reduced overall survival, advanced stage and grade. Downstream retinoic acid receptors (RARG and RARA) were correlated with CRABP2 expression and were associated with worse prognosis in serous EC. The CRABP2 gene signature was enriched for Polycomb target gene sets, and was regulated by ELP3 and BMP7. BMP7 expression was increased in the CRABP2-high group, was associated withworse prognosis, and CRISPR-Cas9 screens revealed correlations in its cell-fitness scorewith CRABP2 following gene knockout. The opposite was true for ELP3, suggesting opposing effects from both master regulators. Conclusions. CRABP2 expression is associated with poor prognosis and advanced EC. The expression of RARA and RARG correlates with CRABP2 and are associated with worse prognosis in advanced histological subtypes. Polycomb target gene sets and two master regulators, ELP3 and BMP7, were identified as functionally relevant mechanisms driving aberrant CRABP2 expression. (c) 2022 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available